Diligence memo · auto-generated · as of July 2, 2026
Stemgent, Inc.
Stemgent, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Stemgent, Inc. operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Stemgent, Inc. has raised $38M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2012-06-04.
Most recent recorded round closed around 2012-06-04.
Valuation (modeled)modeled
Provath models Stemgent, Inc. at approximately $409M (range $12M–$2.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.04× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 14.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotechnology peers (4293 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.